- 3.5 Million U.S. Kids Under 5 Facing Hunger: Study
- New Schizophrenia Drug Approved by FDA
- FDA OKs Avastin as Brain Cancer Tumor Treatment
Here are some of the latest health and medical news developments, compiled by editors of HealthDay:
3.5 Million U.S. Kids Under 5 Facing Hunger: Study
About 17 percent (3.5 million) of American children under the age 5 are at risk of going hungry, according to a report released Thursday by the nonprofit, anti-hunger group Feeding America.
The group's analysis of 2005-2007 data from the U.S. Census Bureau and the Agriculture Department revealed that in 11 states, more than 20 percent of children under age 5 may go hungry, the Associated Press reported.
Louisiana had the highest rate (just under 25 percent), followed by North Carolina, Ohio, Kentucky, Texas, New Mexico, Kansas, South Carolina, Tennessee, Idaho and Arkansas.
Young children who go hungry can suffer lasting physical and behavioral problems, as well as poorer development and academic achievement, the AP reported.
Agriculture Department data shows that, before the current economic crisis, 11 percent of U.S. households lacked enough food for an active, healthy life.
New Schizophrenia Drug Approved by FDA
A new pill to treat adults with schizophrenia has been approved by the U.S. Food and Drug Administration.
Fanapt (iloperidone), which belongs to the atypical antipsychotic class of drugs, is not approved for patients with dementia-related psychosis, United Press International reported.
The FDA ordered that Fanapt carry a boxed warning about the increased risk of death associated with off-label use of the drug to treat behavioral problems in patients with dementia-related psychosis.
Fanapt is made by Patheon Inc., in Ontario, Canada, for Vanda Pharmaceuticals Inc., of Rockville, Md., UPI reported.
FDA OKs Avastin as Brain Cancer Tumor Treatment
It had been more than 10 years since a new treatment for glioblastoma was approved, but the U.S. Food and Drug Administration has now granted accelerated approval for the cancer drug Avastin for use against the aggressive brain cancer tumors, Business Week reports.
Avastin, developed by Genentech, which in March was bought by Switzerland-based Roche, is already approved as treatment for various forms of colon, breast and lung cancers, Business Week said. The FDA go-ahead was based on the drug's ability to achieve a partial or complete response in clinical trials, although Genentech said there is currently no data showing it reduces symptoms or improves survival. The company said it is planning a late stage trial of Avastin as a treatment for newly diagnosed glioblastoma.
About 10,000 people in the United States have glioblastoma -- the same type of tumor Sen. Edward M. Kennedy, D-Mass., has been fighting -- and the tumors often recur even after initial treatment, Genentech said in a news release, Business Week reported.
Copyright © 2011 HealthDay. All rights reserved.